News
GMAB
30.17
-1.50%
-0.46
Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)
TipRanks · 1d ago
Genmab Price Target Maintained With a $32.00/Share by Morgan Stanley
Dow Jones · 2d ago
Genmab Is Maintained at Underweight by Morgan Stanley
Dow Jones · 2d ago
Morgan Stanley Maintains Underweight on Genmab, Maintains $32 Price Target
Benzinga · 2d ago
Analyst Ratings For Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. The company has an average price target of $49.67. 6 analysts have shared their insights on Genmab in the past three months. The 12-month price targets have decreased by 0.16%. The company faces challenges with a decline in revenue growth over the past year.
Benzinga · 2d ago
Genmab Price Target Maintained With a $50.00/Share by Truist Securities
Dow Jones · 2d ago
Truist Securities Maintains Buy on Genmab, Maintains $50 Price Target
Benzinga · 2d ago
Truist Financial Remains a Buy on Genmab (GMAB)
TipRanks · 2d ago
Genmab Launches Multi-Billion Share Buy-back
TipRanks · 2d ago
Weekly Report: what happened at GMAB last week (0318-0322)?
Weekly Report · 3d ago
Genmab A/S Announces Share Capital and Warrant Updates
TipRanks · 6d ago
EUROPE RESEARCH ROUNDUP-Biomerieux, Pernod Ricard, Remy Cointreau
Analysts revise their ratings and price targets on several European companies. Biomerieux, Pernod Ricard, Remy Cointreau among those with revised targets. Berenberg raises target price to buy from hold for British Land. Morgan Stanley raises price targets for several companies.
Reuters · 03/21 07:23
Genmab Completes Share Buy-Back Program
TipRanks · 03/18 21:29
Weekly Report: what happened at GMAB last week (0311-0315)?
Weekly Report · 03/18 09:11
Genmab announces ~$510M worth of share buybacks
Danish biotech Genmab (GMAB) announced a program to repurchase DKK 3.5B worth of its shares. The buybacks will kick off on March 18, 2024, and run through December 16, 2024. The shares of the cancer drug developer have lost more than 21% over the past six months.
Seeking Alpha · 03/15 13:26
Weekly Report: what happened at GMAB last week (0304-0308)?
Weekly Report · 03/11 09:11
Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 03/06 13:14
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
Immunocore Holdings (IMCR) and Springworks Therapeutics (SWTX) and Genmab (GMAB) have 3 analysts with bullish sentiments on the Healthcare sector. 3 analysts just reiterated a Buy rating on Immunocore and 2 others on Springworks. The 3 stocks are most likely to make moves following insider activities.
TipRanks · 03/06 11:40
Weekly Report: what happened at GMAB last week (0226-0301)?
Weekly Report · 03/04 09:11
Truist Financial Reaffirms Their Buy Rating on Genmab (GMAB)
Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB) The company’s shares closed yesterday at $27.77. The company is specialized in developing antibody therapeutics for the treatment of cancer.
TipRanks · 03/01 12:35
More
Webull provides a variety of real-time GMAB stock news. You can receive the latest news about Genmab through multiple platforms. This information may help you make smarter investment decisions.
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.